Ofatumumab for treating relapsing multiple sclerosis [ID1677]
In development [GID-TA10557] Expected publication date: TBC
Search results
557 results
-
-
Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours [ID1626]
In development [GID-TA10523] Expected publication date: TBC
-
Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer
In development [GID-IPG10205] Expected publication date: TBC
-
Prophylactic or therapeutic use of endoanchoring systems in endovascular aortic aneurysm repair (EVAR/TEVAR)
In development [GID-IPG10203] Expected publication date: TBC
-
Total hip arthroplasty using the superpath approach for osteoarthritis
In development [GID-IPG10204] Expected publication date: TBC
-
Upadacitinib for previously treated moderate active rheumatoid arthritis [ID3878]
In development [GID-TA10759] Expected publication date: TBC
-
Pembrolizumab with chemotherapy for treating recurrent, persistent or metastatic cervical cancer [ID3798]
In development [GID-TA10669] Expected publication date: TBC
-
Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia [ID2708]
In development [GID-TA10588] Expected publication date: TBC
-
Neratinib for treating HER2-positive breast cancer after 2 therapies [ID1381]
In development [GID-TA10539] Expected publication date: 15 December 2021
-
Transcervical ultrasound-guided radiofrequency ablation for symptomatic uterine fibroids
In development [GID-IPG10147] Expected publication date: 31 March 2021
-
Extracorporeal whole liver perfusion for acute liver failure
In development [GID-IPG10164] Expected publication date: 31 March 2021
-
Elexacaftor, tezacaftor and ivacaftor fixed dose combination therapy for treating cystic fibrosis with the F508del mutation [ID1661]
In development [GID-TA10566] Expected publication date: TBC
-
Nivolumab for treating resected high-risk invasive urothelial cancer [ID2694]
In development [GID-TA10742] Expected publication date: TBC
-
Solriamfetol for treating excessive waketime sleepiness caused by narcolepsy [ID1602]
In development [GID-TA10524] Expected publication date: TBC
-
Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea [ID1499]
In development [GID-TA10430] Expected publication date: TBC
-
Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea ID1065
In development [GID-TA10385] Expected publication date: TBC
-
Nivolumab with platinum-based chemotherapy for advanced unresectable, recurrent or metastatic previously untreated oesophageal cancer [ID2712]
In development [GID-TA10572] Expected publication date: TBC
-
Olaparib for treating BRCA 1 or 2 mutated metastatic breast cancer after prior chemotherapy [ID1382]
In development [GID-TA10342] Expected publication date: TBC
-
Nivolumab with temozolomide and radiotherapy for newly diagnosed glioblastoma with MGMT methylation [ID1582]
In development [GID-TA10495] Expected publication date: 18 August 2021
-
Nivolumab in combination with chemotherapy for untreated advanced gastric or gastro-oesophageal junction cancer [ID1465]
In development [GID-TA10352] Expected publication date: 13 October 2021
-
Nivolumab for previously treated unresectable advanced oesophageal cancer [ID1249]
In development [GID-TA10222] Expected publication date: TBC
-
Daratumumab in combination for untreated systemic amyloid light-chain amyloidosis [ID3748]
In development [GID-TA10656] Expected publication date: 02 March 2022
-
Mogamulizumab for previously treated T-cell leukaemia-lymphoma [ID1390]
In development [GID-TA10464] Expected publication date: TBC
-
Olaparib for previously treated, hormone-relapsed metastatic prostate cancer with homologous recombination repair gene mutations [ID1640]
In development [GID-TA10584] Expected publication date: 05 May 2021
-
Pertuzumab with trastuzumab emtansine for adjuvant treatment of early HER2-positive breast cancer [ID2711]
In development [GID-TA10591] Expected publication date: TBC
-
Atherothrombotic events - vorapaxar [ID616]
In development [GID-TAG493] Expected publication date: TBC
-
Head and neck cancer - intensity modulated radiotherapy [ID15]
In development [GID-TAG397] Expected publication date: TBC
-
Glaucoma - lerdelimumab (CAT-152) [ID383]
In development [GID-TAG381] Expected publication date: TBC
-
Endoscopic balloon dilation for subglottic or tracheal stenosis
In development [GID-IPG10184] Expected publication date: TBC
-
Laparoscopic morcellation of uterine fibroids
In development [GID-IPG10185] Expected publication date: TBC
-
Endovascular forearm arteriovenous fistula creation for haemodialysis access
In development [GID-IPG10186] Expected publication date: TBC
-
Endoscopic full thickness removal of gastrointestinal stromal tumours of the stomach
In development [GID-IPG10187] Expected publication date: TBC
-
Avelumab for treating metastatic Merkel cell carcinoma (CDF Review of TA517) ID1617
In development [GID-TA10545] Expected publication date: 21 April 2021
-
Tucatinib with trastuzumab and capecitabine for treating HER2-positive unresectable or metastatic advanced breast cancer after 2 or more anti-HER2 therapies [ID3828]
In development [GID-TA10708] Expected publication date: TBC
-
Idebenone for treating Duchenne muscular dystrophy ID1092
In development [GID-TA10310] Expected publication date: TBC
-
Bimekizumab for treating moderate to severe chronic plaque psoriasis [ID2692]
In development [GID-TA10649] Expected publication date: 22 September 2021
-
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection [ID3835]
In development [GID-TA10756] Expected publication date: 22 September 2021
-
Nivolumab with ipilimumab for adjuvant treatment of completely resected stage III or IV melanoma ID1610
In development [GID-TA10499] Expected publication date: TBC
-
Ivosidenib for treating relapsed or refractory IDH1-positive acute myeloid leukaemia [ID1548]
In development [GID-TA10416] Expected publication date: TBC
-
Electrohydraulic lithotripsy for difficult-to-treat bile duct stones
In development [GID-IPG10151] Expected publication date: 28 April 2021
-
Permanent His-bundle pacemaker implantation for heart failure
In development [GID-IPG10145] Expected publication date: 28 April 2021
-
Deep brain stimulation for chronic, severe, treatment-resistant obsessive-compulsive disorder in adults
In development [GID-IPG10143] Expected publication date: 28 April 2021
-
Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]
In development [GID-TA10597] Expected publication date: 27 October 2021
-
Secukinumab for treating non-radiographic axial spondyloarthritis [ID1419]
In development [GID-TA10457] Expected publication date: 19 May 2021
-
Atrial fibrillation - vernakalant [ID454]
In development [GID-TAG428] Expected publication date: TBC
-
Minimally invasive meshless and dissectionless anchoring system for pelvic organ prolapse repair
In development [GID-IPG10191] Expected publication date: TBC
-
Superfcial vein arterialisation and selective venous embolisation for critical limb ischaemia
In development [GID-IPG10192] Expected publication date: TBC
-
Percutaneous endovascular forearm-arteriovenous fistula creation for haemodialysis access
In development [GID-IPG10193] Expected publication date: TBC
-
Tunnelled peritoneal drainage catheter insertion for treatment-resistant, recurrent ascites due to cirrhosis
In development [GID-IPG10194] Expected publication date: TBC
-
Regional nerve graft to restore corneal sensation
In development [GID-IPG10195] Expected publication date: TBC